×
About 135 results

ALLMedicine™ Hyperviscosity Syndrome Center

Research & Reviews  51 results

The utility of therapeutic plasma exchange in Hyperviscosity syndrome associated with j...
https://doi.org/10.1002/jca.21903
Journal of Clinical Apheresis; Green AP, Gonzalez AC et. al.

May 5th, 2021 - Hyperviscosity syndrome (HVS) is a life-threatening syndrome caused by high concentrations of large plasma proteins like IgM, rheumatoid factor, and other immune complexes, leading to increased blood viscosity and symptoms such as visual abnormali...

Reflections on the unexpected laboratory finding of hemorheological alterations observe...
https://doi.org/10.1016/j.mvr.2021.104171
Microvascular Research; Caimi G, Lo Presti R et. al.

Apr 17th, 2021 - Hyperviscosity syndrome is a clinical condition characterized by the slowing of blood flow through the vessels and it may be associated with several diseases. The nosographic classification of primary hyperviscosity conditions (Wells classificatio...

Profound Sudden Sensorineural Hearing Loss in Hematologic Malignancy: A Case for Urgent...
https://doi.org/10.1097/MAO.0000000000003131
Otology & Neurotology : Official Publication of the Ameri... Dumberger LD, Hwa TP et. al.

Mar 31st, 2021 - To perform a systematic review of sensorineural hearing loss (SNHL) in hematologic malignancy; to describe an illustrative case of urgent cochlear implantation for bilateral profound SNHL and vestibular hypofunction in hyperviscosity syndrome; to ...

Hyperviscosity-related retinopathy and serous macular detachment in Waldenström's macro...
https://doi.org/10.1177/11206721211002066
European Journal of Ophthalmology; Lai CC, Chang CH

Mar 16th, 2021 - To present a 5-year mortal case of Waldenström's macroglobulinemia-related retinopathy and serous macular detachment. A 63-year-old man, with unremarkable medical history, presented with bilateral decreased vision for 2 months. Fundus examination ...

Efficacy of plasmapheresis as treatment for bilateral hyperviscosity syndrome related r...
https://doi.org/10.1177/1120672121997069
European Journal of Ophthalmology; Merz T, Marchesoni I et. al.

Feb 20th, 2021 - To report a case of good clinical response to plasmapheresis as therapy for a bilateral hyperviscosity syndrome related retinopathy in a young patient with undiagnosed multiple myeloma (MM). Case report. A 48-year-old caucasian man, previously dia...

see more →

News  3 results

Fast Five Quiz: Waldenström Macroglobulinemia Workup
https://reference.medscape.com/viewarticle/944100

Feb 1st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...

Age and race affect access to myeloma treatment
https://www.mdedge.com/hematology-oncology/article/162787/multiple-myeloma/age-and-race-affect-access-myeloma-treatment/page/0/1

Apr 6th, 2018 - Similarly increased odds of no treatment were reported for patients with comorbidities and poor performance status indicators. “In a subset of older and frail patients, the risks of treatments approved for [multiple myeloma] might outweigh the ben.

Mayo experts outline Waldenström macroglobulinemia management
https://www.mdedge.com/hematologynews/nhlhub/article/152579/indolent-lymphoma/mayo-experts-outline-waldenstrom
Mary Ellen Schneider

Nov 21st, 2017 - Four to six cycles of bendamustine/rituximab is the primary regimen of choice for symptomatic, treatment-naive patients with Waldenström macroglobulinemia, especially when rapid control is needed for bulky disease, according to treatment guideline.

see more →